Vitexin attenuates chronic kidney disease by inhibiting renal tubular epithelial cell ferroptosis via NRF2 activation.

Jiayu SongHongri WangJingyi ShengWen ZhangJuan LeiWeihua GanFangfang CaiYunwen Yang

Published in: Molecular medicine (Cambridge, Mass.) (2023)

Taken together, our results indicate that vitexin can protect against renal tubular epithelial cell ferroptosis in CKD by activating the KEAP1/NRF2/HO-1 pathway and is a promising drug to treat CKD.

Keyphrases

chronic kidney disease
end stage renal disease
cell death
oxidative stress
signaling pathway
high glucose
pi k akt
emergency department
endothelial cells
protein protein
adverse drug
cell proliferation
electronic health record